SURMOUNT-5 HEAD-TO-HEAD, OPEN-LABEL DATA 1
SUPERIOR body weight reduction with Mounjaro vs Wegovy ®( semaglutide) 1 †
NEW!
SURMOUNT-5 HEAD-TO-HEAD, OPEN-LABEL DATA 1
REVOLUTIONISING * chronic weight management 1 – 4
* The only registered single agent that activates both GIP and GLP-1 receptors. 2, 3
SUPERIOR body weight reduction with Mounjaro vs Wegovy ®( semaglutide) 1 †
Hypothetical patient.
† At 72 weeks, patients taking Mounjaro MTD( maximum tolerated dose; 10 mg or 15 mg) experienced superior mean percentage body weight reduction from baseline of-20.2 % vs-13.7 % in those taking Wegovy MTD( 1.7 mg or 2.4 mg) using the modified treatment-regimen estimand( TRE; 47 % relative reduction), or-21.6 % vs-15.4 %, respectively, using the efficacy estimand( EE; 40 % relative reduction), p < 0.001 for both, adjusted for multiplicity, mITT population. 1
Indications: Mounjaro is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management, including weight loss and weight maintenance, in adults with an initial body mass index( BMI) of ≥30 kg / m 2( obesity) or ≥27 kg / m 2 to < 30 kg / m 2( overweight) in the presence of at least one weight-related comorbid condition( e. g., hypertension, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease, prediabetes or type 2 diabetes mellitus). 2
SURMOUNT-5 study design: Phase 3b, head-to-head, open-label clinical trial which assessed the efficacy and safety of Mounjaro vs Wegovy in 750 adults living with obesity( BMI of ≥30 kg / m 2) or overweight( BMI of ≥27 kg / m 2) and ≥1 weight-related complication, excluding type 2 diabetes. Participants in all arms also received instructions for a reduced-calorie diet and increased physical activity. 1
Limitations of an open-label study may be related to a bias in evaluation of the outcomes, efficacy and / or safety, and analysis was not tested against a placebo-controlled comparison group. However, the consistency of the current findings with those from previous blinded studies support their generalisability. 1
TRE: Evaluated the treatment effect regardless of premature discontinuation of the trial drug or initiation of other medications for obesity management. 1 EE: Evaluated the treatment effect among participants who had stayed on treatment and not taken other anti-obesity therapies. 1 BMI = body mass index; GIP = glucose-dependent insulinotropic polypeptide; GLP-1 = glucagon-like peptide-1; mITT = modified intention-to-treat; MTD = maximum tolerated dose.
References: 1. Aronne LJ, et al. N Engl J Med 2025; doi: 10.1056 / NEJMoa2416394( including supplement and protocol). 2. MOUNJARO ® Approved Product Information. 3. Willard FS, et al. JCI Insight 2020; 5( 17): e140532. 4. Jastreboff AM, et al. N Engl J Med 2022; 387( 3): 205 – 16( including Supplement and Protocol).